25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

RENB (Renovaro Biosciences Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Renovaro Biosciences Inc together

I guess you are interested in Renovaro Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Renovaro Biosciences Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Renovaro Biosciences Inc’s Price Targets

I'm going to help you getting a better view of Renovaro Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Renovaro Biosciences Inc

I send you an email if I find something interesting about Renovaro Biosciences Inc.

1. Quick Overview

1.1. Quick analysis of Renovaro Biosciences Inc (30 sec.)










1.2. What can you expect buying and holding a share of Renovaro Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.51
Expected worth in 1 year
$0.05
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-0.47
Return On Investment
-161.3%

For what price can you sell your share?

Current Price per Share
$0.29
Expected price per share
$0.27 - $0.448
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Renovaro Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)
$0.29
Intrinsic Value Per Share
$1,009,769.40 - $4,045,620.02
Total Value Per Share
$1,009,769.92 - $4,045,620.53

2.2. Growth of Renovaro Biosciences Inc (5 min.)




Is Renovaro Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$88.3m$76.3m$41.3m35.2%

How much money is Renovaro Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$9.9m-$23.9m$14m140.8%
Net Profit Margin-2,167.4%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Renovaro Biosciences Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Renovaro Biosciences Inc?

Welcome investor! Renovaro Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Renovaro Biosciences Inc.

First you should know what it really means to hold a share of Renovaro Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Renovaro Biosciences Inc is $0.2889. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Renovaro Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Renovaro Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.51. Based on the TTM, the Book Value Change Per Share is $-0.12 per quarter. Based on the YOY, the Book Value Change Per Share is $0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Renovaro Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.000.4%-0.06-20.0%-0.14-48.2%-0.12-41.2%-0.09-30.1%-0.05-17.0%
Usd Book Value Change Per Share0.0412.7%-0.12-40.3%0.1551.5%-0.04-12.2%-0.02-8.2%0.014.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.0412.7%-0.12-40.3%0.1551.5%-0.04-12.2%-0.02-8.2%0.014.3%
Usd Price Per Share0.54-0.90-2.71-1.68-3.08-3.49-
Price to Earnings Ratio123.51-28.20--13.52-2.74--15.09--103.48-
Price-to-Total Gains Ratio14.77-3.21-744.02-259.44-127.78--277.32-
Price to Book Ratio1.06-1.31-8.44-4.39-4.79--12.89-
Price-to-Total Gains Ratio14.77-3.21-744.02-259.44-127.78--277.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2889
Number of shares3461
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.12-0.02
Usd Total Gains Per Share-0.12-0.02
Gains per Quarter (3461 shares)-403.21-82.28
Gains per Year (3461 shares)-1,612.85-329.12
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1613-16230-329-339
20-3226-32360-658-668
30-4839-48490-987-997
40-6451-64620-1316-1326
50-8064-80750-1646-1655
60-9677-96880-1975-1984
70-11290-113010-2304-2313
80-12903-129140-2633-2642
90-14516-145270-2962-2971
100-16129-161400-3291-3300

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%2.038.00.05.0%2.053.00.03.6%
Book Value Change Per Share1.02.01.025.0%4.07.01.033.3%6.013.01.030.0%11.028.01.027.5%14.040.01.025.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.055.00.0%
Total Gains per Share1.02.01.025.0%4.07.01.033.3%6.013.01.030.0%11.028.01.027.5%14.040.01.025.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Renovaro Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.037-0.117+417%0.149-75%-0.035+196%-0.024+165%0.012+195%
Book Value Per Share--0.5140.684-25%0.444+16%0.5160%0.694-26%0.556-8%
Current Ratio--0.1270.078+63%0.164-22%0.840-85%2.895-96%4.493-97%
Debt To Asset Ratio--0.2490.227+10%0.211+18%0.185+35%0.142+75%0.521-52%
Debt To Equity Ratio--0.3320.296+12%0.269+24%0.234+42%0.175+90%0.342-3%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--65044354.344122492762.524-47%447636902.313-85%270417159.144-76%518071890.744-87%608726452.411-89%
Eps--0.001-0.058+5362%-0.139+12772%-0.119+10922%-0.087+8021%-0.049+4560%
Ev To Ebitda Ratio---3.937-2.371-40%-17.864+354%-8.517+116%-23.094+487%-99.687+2432%
Free Cash Flow Per Share--68582.24217145.549+300%-0.016+100%5715.173+1100%3429.094+1900%1714.543+3900%
Free Cash Flow To Equity Per Share--42350.13310587.533+300%-0.002+100%3529.174+1100%2117.513+1900%1058.758+3900%
Gross Profit Margin--1.0001.0020%1.0000%1.0020%1.0010%1.0010%
Intrinsic Value_10Y_max--4045620.017----------
Intrinsic Value_10Y_min--1009769.403----------
Intrinsic Value_1Y_max--78343.052----------
Intrinsic Value_1Y_min--23027.680----------
Intrinsic Value_3Y_max--484644.173----------
Intrinsic Value_3Y_min--137293.490----------
Intrinsic Value_5Y_max--1191451.828----------
Intrinsic Value_5Y_min--325323.309----------
Market Cap49725181.411-88%93460621.344155414858.274-40%467156805.563-80%289066702.311-68%530759081.994-82%600494819.276-84%
Net Profit Margin----21.6740%-0%-7.2250%-4.3350%-161.1020%
Operating Margin----71.9500%-0%-23.9830%-14.3900%-176.8490%
Operating Ratio---70.796-100%-0%23.599-100%14.159-100%163.557-100%
Pb Ratio0.563-88%1.0571.307-19%8.444-87%4.385-76%4.792-78%-12.890+1319%
Pe Ratio65.713-88%123.51028.202+338%-13.516+111%2.738+4411%-15.086+112%-103.478+184%
Price Per Share0.289-88%0.5430.903-40%2.714-80%1.679-68%3.084-82%3.489-84%
Price To Free Cash Flow Ratio0.000-88%0.000-12.778+645538335%-41.500+2096621227%-2468.227+124697285580%-1506.875+76128812872%-899.972+45467466648%
Price To Total Gains Ratio7.859-88%14.7703.206+361%744.020-98%259.438-94%127.782-88%-277.320+1978%
Quick Ratio--0.0570.033+73%0.106-46%0.670-92%2.725-98%4.334-99%
Return On Assets--0.002-0.060+3836%-0.228+14308%-0.202+12665%-0.136+8558%-0.227+14197%
Return On Equity--0.002-0.077+3679%-0.287+13520%-0.245+11545%-0.163+7720%-0.159+7536%
Total Gains Per Share--0.037-0.117+417%0.149-75%-0.035+196%-0.024+165%0.012+195%
Usd Book Value--88386851.000117754717.250-25%76359878.750+16%88744039.5830%119409528.800-26%95684115.975-8%
Usd Book Value Change Per Share--0.037-0.117+417%0.149-75%-0.035+196%-0.024+165%0.012+195%
Usd Book Value Per Share--0.5140.684-25%0.444+16%0.5160%0.694-26%0.556-8%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--65044354.344122492762.524-47%447636902.313-85%270417159.144-76%518071890.744-87%608726452.411-89%
Usd Eps--0.001-0.058+5362%-0.139+12772%-0.119+10922%-0.087+8021%-0.049+4560%
Usd Free Cash Flow--11804307399919.0002951074940937.250+300%-2718070.000+100%983689926838.111+1100%590212175994.617+1900%295105427296.883+3900%
Usd Free Cash Flow Per Share--68582.24217145.549+300%-0.016+100%5715.173+1100%3429.094+1900%1714.543+3900%
Usd Free Cash Flow To Equity Per Share--42350.13310587.533+300%-0.002+100%3529.174+1100%2117.513+1900%1058.758+3900%
Usd Market Cap49725181.411-88%93460621.344155414858.274-40%467156805.563-80%289066702.311-68%530759081.994-82%600494819.276-84%
Usd Price Per Share0.289-88%0.5430.903-40%2.714-80%1.679-68%3.084-82%3.489-84%
Usd Profit--189176.000-9954810.250+5362%-23973117.750+12772%-20202877.750+10779%-14822633.800+7935%-8266832.300+4470%
Usd Revenue---45363.500-100%-0%15121.167-100%9072.700-100%5611.675-100%
Usd Total Gains Per Share--0.037-0.117+417%0.149-75%-0.035+196%-0.024+165%0.012+195%
 EOD+4 -4MRQTTM+20 -15YOY+16 -163Y+18 -175Y+18 -1710Y+20 -15

3.3 Fundamental Score

Let's check the fundamental score of Renovaro Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1565.713
Price to Book Ratio (EOD)Between0-10.563
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.057
Current Ratio (MRQ)Greater than10.127
Debt to Asset Ratio (MRQ)Less than10.249
Debt to Equity Ratio (MRQ)Less than10.332
Return on Equity (MRQ)Greater than0.150.002
Return on Assets (MRQ)Greater than0.050.002
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Renovaro Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.893
Ma 20Greater thanMa 500.335
Ma 50Greater thanMa 1000.328
Ma 100Greater thanMa 2000.503
OpenGreater thanClose0.288
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Renovaro Biosciences Inc

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Fundamental data was last updated by Penke on 2025-06-16 06:27:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Renovaro Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Renovaro Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,167.4%+2,167.4%
TTM-2,167.4%YOY--2,167.4%
TTM-2,167.4%5Y-433.5%-1,734.0%
5Y-433.5%10Y-16,110.2%+15,676.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM-2,167.4%-139.0%-2,028.4%
YOY--194.4%+194.4%
3Y-722.5%-248.5%-474.0%
5Y-433.5%-343.3%-90.2%
10Y-16,110.2%-488.9%-15,621.3%
4.3.1.2. Return on Assets

Shows how efficient Renovaro Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • 0.2% Return on Assets means that Renovaro Biosciences Inc generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Renovaro Biosciences Inc:

  • The MRQ is 0.2%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -6.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.2%TTM-6.0%+6.2%
TTM-6.0%YOY-22.8%+16.8%
TTM-6.0%5Y-13.6%+7.6%
5Y-13.6%10Y-22.7%+9.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2%-11.6%+11.8%
TTM-6.0%-11.7%+5.7%
YOY-22.8%-11.4%-11.4%
3Y-20.2%-11.9%-8.3%
5Y-13.6%-12.1%-1.5%
10Y-22.7%-13.8%-8.9%
4.3.1.3. Return on Equity

Shows how efficient Renovaro Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • 0.2% Return on Equity means Renovaro Biosciences Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Renovaro Biosciences Inc:

  • The MRQ is 0.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -7.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.2%TTM-7.7%+7.9%
TTM-7.7%YOY-28.7%+21.1%
TTM-7.7%5Y-16.3%+8.6%
5Y-16.3%10Y-15.9%-0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2%-13.5%+13.7%
TTM-7.7%-15.0%+7.3%
YOY-28.7%-14.5%-14.2%
3Y-24.5%-16.9%-7.6%
5Y-16.3%-17.9%+1.6%
10Y-15.9%-19.9%+4.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Renovaro Biosciences Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Renovaro Biosciences Inc is operating .

  • Measures how much profit Renovaro Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Renovaro Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-7,195.0%+7,195.0%
TTM-7,195.0%YOY--7,195.0%
TTM-7,195.0%5Y-1,439.0%-5,756.0%
5Y-1,439.0%10Y-17,684.9%+16,245.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM-7,195.0%-249.7%-6,945.3%
YOY--208.4%+208.4%
3Y-2,398.3%-221.7%-2,176.6%
5Y-1,439.0%-344.1%-1,094.9%
10Y-17,684.9%-470.4%-17,214.5%
4.3.2.2. Operating Ratio

Measures how efficient Renovaro Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM70.796-70.796
TTM70.796YOY-+70.796
TTM70.7965Y14.159+56.637
5Y14.15910Y163.557-149.397
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.108-2.108
TTM70.7962.680+68.116
YOY-3.080-3.080
3Y23.5993.621+19.978
5Y14.1594.734+9.425
10Y163.5576.546+157.011
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Renovaro Biosciences Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Renovaro Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.13 means the company has $0.13 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 0.127. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.078. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.127TTM0.078+0.049
TTM0.078YOY0.164-0.086
TTM0.0785Y2.895-2.817
5Y2.89510Y4.493-1.598
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1273.659-3.532
TTM0.0783.834-3.756
YOY0.1644.141-3.977
3Y0.8404.661-3.821
5Y2.8955.756-2.861
10Y4.4936.151-1.658
4.4.3.2. Quick Ratio

Measures if Renovaro Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.06 means the company can pay off $0.06 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 0.057. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.033. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.057TTM0.033+0.024
TTM0.033YOY0.106-0.073
TTM0.0335Y2.725-2.692
5Y2.72510Y4.334-1.609
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0572.799-2.742
TTM0.0333.143-3.110
YOY0.1063.794-3.688
3Y0.6704.307-3.637
5Y2.7255.707-2.982
10Y4.3346.457-2.123
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Renovaro Biosciences Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Renovaro Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Renovaro Biosciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.25 means that Renovaro Biosciences Inc assets are financed with 24.9% credit (debt) and the remaining percentage (100% - 24.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 0.249. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.227. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.249TTM0.227+0.022
TTM0.227YOY0.211+0.016
TTM0.2275Y0.142+0.085
5Y0.14210Y0.521-0.378
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2490.324-0.075
TTM0.2270.347-0.120
YOY0.2110.329-0.118
3Y0.1850.340-0.155
5Y0.1420.349-0.207
10Y0.5210.379+0.142
4.5.4.2. Debt to Equity Ratio

Measures if Renovaro Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 33.2% means that company has $0.33 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 0.332. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.296. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.332TTM0.296+0.036
TTM0.296YOY0.269+0.027
TTM0.2965Y0.175+0.121
5Y0.17510Y0.342-0.167
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3320.379-0.047
TTM0.2960.435-0.139
YOY0.2690.412-0.143
3Y0.2340.446-0.212
5Y0.1750.460-0.285
10Y0.3420.509-0.167
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Renovaro Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • A PE ratio of 123.51 means the investor is paying $123.51 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Renovaro Biosciences Inc:

  • The EOD is 65.713. Based on the earnings, the company is expensive. -2
  • The MRQ is 123.510. Based on the earnings, the company is expensive. -2
  • The TTM is 28.202. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD65.713MRQ123.510-57.797
MRQ123.510TTM28.202+95.308
TTM28.202YOY-13.516+41.718
TTM28.2025Y-15.086+43.288
5Y-15.08610Y-103.478+88.392
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD65.713-2.282+67.995
MRQ123.510-2.062+125.572
TTM28.202-2.541+30.743
YOY-13.516-3.722-9.794
3Y2.738-3.754+6.492
5Y-15.086-6.100-8.986
10Y-103.478-6.653-96.825
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Renovaro Biosciences Inc:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 0.000. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -12.778. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ0.0000.000
MRQ0.000TTM-12.778+12.778
TTM-12.778YOY-41.500+28.722
TTM-12.7785Y-1,506.875+1,494.097
5Y-1,506.87510Y-899.972-606.903
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-3.101+3.101
MRQ0.000-2.689+2.689
TTM-12.778-3.594-9.184
YOY-41.500-4.363-37.137
3Y-2,468.227-5.065-2,463.162
5Y-1,506.875-8.478-1,498.397
10Y-899.972-9.273-890.699
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Renovaro Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.06 means the investor is paying $1.06 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Renovaro Biosciences Inc:

  • The EOD is 0.563. Based on the equity, the company is cheap. +2
  • The MRQ is 1.057. Based on the equity, the company is underpriced. +1
  • The TTM is 1.307. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.563MRQ1.057-0.495
MRQ1.057TTM1.307-0.249
TTM1.307YOY8.444-7.137
TTM1.3075Y4.792-3.485
5Y4.79210Y-12.890+17.682
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5631.932-1.369
MRQ1.0571.848-0.791
TTM1.3072.119-0.812
YOY8.4442.469+5.975
3Y4.3852.526+1.859
5Y4.7923.667+1.125
10Y-12.8904.351-17.241
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Renovaro Biosciences Inc.

4.8.1. Institutions holding Renovaro Biosciences Inc

Institutions are holding 12.846% of the shares of Renovaro Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc4.27530.0001735854085694013.1804
2025-03-31Vanguard Group Inc3.28860.00015660333-58461-1.0223
2025-03-31Geode Capital Management, LLC1.37560.00012367658350241.5015
2025-03-31State Street Corp1.163802003190-61669-2.9866
2025-03-31Northern Trust Corp0.48360.0001832288-57069-6.4169
2024-12-31UBS Group AG0.44370.00017637017172451543.9233
2025-03-31Charles Schwab Investment Management Inc0.2104036212600
2025-03-31Bank of New York Mellon Corp0.13960240244163297.2925
2025-03-31Morgan Stanley - Brokerage Accounts0.12120208681-159483-43.3185
2025-03-31Goldman Sachs Group Inc0.10580182054-182425-50.0509
2025-03-31Citadel Advisors Llc0.096501660831660830
2025-03-31Deutsche Bank AG0.091901581703073324.1162
2024-12-31Nuveen Asset Management, LLC0.0881015168185393128.8212
2025-03-31Nuveen, LLC0.088101516811516810
2025-03-31Susquehanna International Group, LLP0.0806013877177045124.8177
2025-03-31JPMorgan Chase & Co0.07490128982-224851-63.5472
2025-03-31Rhumbline Advisers0.07150.0001123006100468.8934
2025-03-31Barclays PLC0.06960119828-60016-33.3711
2024-12-31Commonwealth Equity Services Inc0.0590.000110157300
2025-03-31Citigroup Inc0.0467080362-107155-57.1442
Total 12.37450.000721298952+1235390+5.8%

4.9.2. Funds holding Renovaro Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv1.94160.0001334190000
2025-05-31iShares Russell 2000 ETF1.60790.0014276756900
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.81610.0005140470800
2025-03-31Fidelity Small Cap Index0.66020.00261136326-13093-1.1391
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.54620.000794015800
2025-05-31iShares Russell 2000 Growth ETF0.3520.001760590100
2025-04-30Vanguard Russell 2000 ETF0.330.0017567957313695.846
2025-04-30Fidelity Extended Market Index0.28460.0005489917-4683-0.9468
2025-05-31iShares Russell 2000 Value ETF0.2040.00135118300
2025-04-30Schwab Small Cap Index0.16140.001727772700
2025-03-31NT R2000 Index Fund - NL0.15010.0024258307-20262-7.2736
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.14390.000924760000
2025-05-31iShares Micro-Cap ETF0.13280.009122861000
2025-03-31NT R2000 Index Fund - DC - NL - 30.11990.0024206353-20908-9.2
2025-04-30iShares Russell 2000 Small-Cap Idx Instl0.11580.001819924200
2025-03-31Extended Equity Market Fund K0.10440.00071797491797490
2025-03-31Russell 2500™ Index Fund F0.1010.001173843-37-0.0213
2025-04-30Fidelity Total Market Index0.08880.000115279100
2025-04-30Nuveen Small Cap Blend Idx R60.08810.001815168100
2025-03-31Russell 2000 Index Non-Lendable Fund E0.08650.00251487982360.1589
Total 8.03530.034613830320+152371+1.1%

5.3. Insider Transactions

Insiders are holding 47.272% of the shares of Renovaro Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-07-29Anderson Wittekind WilliamSELL11141.3
2024-07-17Anderson Wittekind WilliamSELL163621.46
2024-07-15Anderson Wittekind WilliamSELL219541.41
2024-07-11Anderson Wittekind WilliamSELL148961.51
2024-07-09Anderson Wittekind WilliamSELL46301.53
2024-07-05Anderson Wittekind WilliamSELL600001.55
2024-07-03Anderson Wittekind WilliamSELL500001.51
2024-07-01Anderson Wittekind WilliamSELL600001.56
2024-06-27Anderson Wittekind WilliamSELL146711.5
2024-06-25Anderson Wittekind WilliamSELL200001.58
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Other Current Liabilities  1,5263,2724,79813,11917,917-5,93711,980-13,124-1,144
Income before Tax  -58,99041,966-17,0241,293-15,7328,479-7,2527,442189
Net Income  -58,99041,966-17,0241,293-15,7328,479-7,2527,442189
Net Income from Continuing Operations  -58,9909,068-49,9225,710-44,21236,960-7,2527,442189



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets117,726
Total Liabilities29,339
Total Stockholder Equity88,387
 As reported
Total Liabilities 29,339
Total Stockholder Equity+ 88,387
Total Assets = 117,726

Assets

Total Assets117,726
Total Current Assets3,668
Long-term Assets114,058
Total Current Assets
Cash And Cash Equivalents 923
Short-term Investments 710
Other Current Assets 2,745
Total Current Assets  (as reported)3,668
Total Current Assets  (calculated)4,378
+/- 710
Long-term Assets
Property Plant Equipment 1,385
Goodwill 112,642
Intangible Assets 16
Long-term Assets Other 14
Long-term Assets  (as reported)114,058
Long-term Assets  (calculated)114,058
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities28,842
Long-term Liabilities498
Total Stockholder Equity88,387
Total Current Liabilities
Short-term Debt 6,534
Short Long Term Debt 5,986
Accounts payable 11,726
Other Current Liabilities -1,144
Total Current Liabilities  (as reported)28,842
Total Current Liabilities  (calculated)23,101
+/- 5,740
Long-term Liabilities
Long-term Liabilities  (as reported)498
Long-term Liabilities  (calculated)0
+/- 498
Total Stockholder Equity
Common Stock16
Retained Earnings -383,730
Accumulated Other Comprehensive Income 776
Other Stockholders Equity 471,325
Total Stockholder Equity (as reported)88,387
Total Stockholder Equity (calculated)88,387
+/-0
Other
Capital Stock16
Cash and Short Term Investments 923
Common Stock Shares Outstanding 163,930
Liabilities and Stockholders Equity 117,726
Net Debt 6,108
Net Invested Capital 94,373
Net Working Capital -25,174
Property Plant and Equipment Gross 1,385
Short Long Term Debt Total 7,031



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-30
> Total Assets 
0
21
13
14
14
16
13
20
13
13
0
911
718
2,552
5,240
3,643
2,100
1,731
1,336
981
871
945
431
382
4,522
3,711
7,827
144,264
182,502
175,797
173,957
169,306
179,877
180,620
178,360
180,509
178,102
175,133
172,885
173,697
189,605
184,065
183,136
180,101
84,633
83,071
80,274
78,731
58,301
57,563
58,018
212,279
212,279
163,129
111,340
117,726
117,726111,340163,129212,279212,27958,01857,56358,30178,73180,27483,07184,633180,101183,136184,065189,605173,697172,885175,133178,102180,509178,360180,620179,877169,306173,957175,797182,502144,2647,8273,7114,5223824319458719811,3361,7312,1003,6435,2402,55271891101313201316141413210
   > Total Current Assets 
0
21
13
14
14
16
13
20
13
13
0
560
423
2,345
5,046
3,476
1,900
1,568
1,193
835
732
785
282
235
4,199
3,161
7,238
17,065
15,762
13,548
13,269
10,507
12,495
11,209
9,063
11,266
8,941
6,066
4,008
4,921
20,899
15,455
14,619
11,696
9,565
8,133
5,389
3,927
2,565
1,906
2,403
1,220
1,220
1,998
1,708
3,668
3,6681,7081,9981,2201,2202,4031,9062,5653,9275,3898,1339,56511,69614,61915,45520,8994,9214,0086,0668,94111,2669,06311,20912,49510,50713,26913,54815,76217,0657,2383,1614,1992352827857328351,1931,5681,9003,4765,0462,34542356001313201316141413210
       Cash And Cash Equivalents 
0
12
0
0
0
2
0
7
0
0
0
54
181
598
3,009
3,435
400
1,048
531
151
23
32
118
34
3,942
2,945
2,306
17,018
15,601
13,405
13,240
10,272
12,282
11,138
8,627
10,939
8,696
5,966
3,425
4,526
20,664
15,377
13,708
11,151
9,172
7,972
4,119
2,948
1,874
523
244
313
313
220
312
923
9233122203133132445231,8742,9484,1197,9729,17211,15113,70815,37720,6644,5263,4255,9668,69610,9398,62711,13812,28210,27213,24013,40515,60117,0182,3062,9453,9423411832231515311,0484003,4353,00959818154000702000120
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
424
147
1,709
2,030
0
0
0
0
0
0
0
0
0
0
0
4,812
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
710
71000000000000000000000000000004,812000000000002,0301,70914742400000000000
       Net Receivables 
0
8
13
13
13
13
13
13
13
13
8
70
85
35
8
41
400
460
582
644
695
746
155
194
224
181
105
31
123
123
3
2
21
15
3
0
2
2
0
0
2
2
0
0
0
0
0
0
0
1,058
1,074
0
0
1,108
127
0
01271,108001,0741,058000000022002203152123123123311051812241941557466956445824604004183585708131313131313131380
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
436
156
1,712
2,030
0
0
60
80
40
14
6
9
7
33
36
4,827
15
38
142
26
232
192
56
434
326
243
100
583
395
233
78
911
545
393
161
1,271
979
691
325
1,086
907
907
669
1,269
2,745
2,7451,2696699079071,0863256919791,27116139354591178233395583100243326434561922322614238154,827363379614408060002,0301,71215643600000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
352
296
207
194
167
200
163
143
145
138
160
149
148
323
550
589
127,199
166,740
162,249
160,688
158,799
167,382
169,411
169,297
169,244
169,161
169,068
168,877
168,776
168,706
168,610
168,518
168,405
75,068
74,938
74,884
74,804
55,735
55,656
55,615
211,059
211,059
161,132
109,632
114,058
114,058109,632161,132211,059211,05955,61555,65655,73574,80474,88474,93875,068168,405168,518168,610168,706168,776168,877169,068169,161169,244169,297169,411167,382158,799160,688162,249166,740127,19958955032314814916013814514316320016719420729635200000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
40
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29
27
334
655
744
688
2,720
2,611
2,563
2,482
2,389
2,307
2,213
2,155
2,064
1,967
1,869
1,744
1,622
1,569
1,493
1,423
1,346
1,310
1,875
1,875
1,752
1,603
1,385
1,3851,6031,7521,8751,8751,3101,3461,4231,4931,5691,6221,7441,8691,9672,0642,1552,2132,3072,3892,4822,5632,6112,72068874465533427290000000000000004000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
67
67
0
0
0
0
0
0
0
0
25
25
25
0
0
11
0
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
164,187
164,187
159,330
107,999
112,642
112,642107,999159,330164,187164,18711,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,6400110025252500000000676700000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196
422
447
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000447422196000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
234
220
199
186
161
200
160
140
143
136
133
122
120
124
125
123
127,138
154,935
150,138
148,255
146,278
154,917
154,913
154,908
154,903
154,901
154,901
154,900
154,893
154,890
154,885
154,879
154,875
61,615
61,611
61,613
61,612
42,651
42,649
42,644
44,976
44,976
30
18
16
16183044,97644,97642,64442,64942,65161,61261,61361,61161,615154,875154,879154,885154,890154,893154,900154,901154,901154,903154,908154,913154,917146,278148,255150,138154,935127,13812312512412012213313614314016020016118619922023400000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
153
0
0
34
0
138
138
138
138
138
0
138
0
138
30
30
21
21
0
22
0
0
62
0
22
0
0
0
0
0
0
0
00000002206200220212130301380138013813813813813803400153300000000000000000000000
> Total Liabilities 
0
19
23
27
38
47
55
71
68
84
79
3,098
3,349
4,933
1,758
972
1,000
1,014
894
1,044
1,508
1,743
1,715
1,988
2,989
951
5,974
906
23,765
22,208
25,239
25,337
6,777
8,438
7,077
10,286
11,830
10,903
10,945
11,379
14,942
17,090
17,517
18,858
12,014
12,746
875
12,603
11,799
10,816
14,423
43,684
43,684
31,152
29,281
29,339
29,33929,28131,15243,68443,68414,42310,81611,79912,60387512,74612,01418,85817,51717,09014,94211,37910,94510,90311,83010,2867,0778,4386,77725,33725,23922,20823,7659065,9749512,9891,9881,7151,7431,5081,0448941,0141,0009721,7584,9333,3493,098798468715547382723190
   > Total Current Liabilities 
0
19
23
27
38
47
55
71
68
84
79
3,098
3,349
4,933
1,758
972
1,000
1,014
894
1,044
1,508
1,410
1,405
1,988
2,989
951
5,974
906
874
785
1,638
1,519
1,110
1,301
1,090
971
1,335
832
1,559
1,408
1,886
1,211
6,202
7,512
6,451
7,159
875
11,773
11,023
10,096
13,758
20,874
20,874
30,310
28,607
28,842
28,84228,60730,31020,87420,87413,75810,09611,02311,7738757,1596,4517,5126,2021,2111,8861,4081,5598321,3359711,0901,3011,1101,5191,6387858749065,9749512,9891,9881,4051,4101,5081,0448941,0141,0009721,7584,9333,3493,098798468715547382723190
       Short-term Debt 
0
14
5
27
5
9
55
64
64
74
77
1,705
1,717
1,611
100
99
0
101
101
103
103
103
103
440
2,090
496
209
0
0
0
0
0
0
256
261
266
271
276
282
287
292
298
5,031
6,281
1,454
1,399
5,804
6,207
5,003
3,877
6,727
0
8,086
2,945
5,692
6,534
6,5345,6922,9458,08606,7273,8775,0036,2075,8041,3991,4546,2815,0312982922872822762712662612560000002094962,0904401031031031031011010991001,6111,7171,705777464645595275140
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
336
1,607
408
447
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,728
6,002
1,200
1,200
4,726
6,001
4,625
3,663
6,509
7,119
2,451
2,607
5,130
5,986
5,9865,1302,6072,4517,1196,5093,6634,6256,0014,7261,2001,2006,0024,7280000000000000004474081,60733600000000000000000000000
       Accounts payable 
0
5
0
0
0
0
0
0
0
0
41
568
669
624
924
823
0
893
623
795
1,185
1,077
1,065
1,228
670
445
934
899
572
713
754
1,270
539
610
628
328
593
282
189
505
321
548
167
487
1,402
4,683
4,555
4,471
5,297
5,421
5,578
7,991
7,991
9,449
10,935
11,726
11,72610,9359,4497,9917,9915,5785,4215,2974,4714,5554,6831,4024871675483215051892825933286286105391,2707547135728999344456701,2281,0651,0771,1857956238930823924624669568410000000050
       Other Current Liabilities 
0
0
17
22
33
38
0
7
3
10
2
824
964
2,699
734
50
0
20
169
147
220
230
238
320
230
11
4,831
7
302
72
884
249
572
435
201
377
471
273
1,088
616
1,273
365
1,004
744
3,595
1,078
933
1,095
723
798
1,453
1,526
4,798
17,917
11,980
-1,144
-1,14411,98017,9174,7981,5261,4537987231,0959331,0783,5957441,0043651,2736161,0882734713772014355722498847230274,83111230320238230220147169200507342,6999648242103703833221700
   > Long-term Liabilities 
0
0
5
0
5
9
55
0
64
74
77
2,273
2,385
2,235
1,024
922
0
994
725
897
1,288
333
310
1,668
2,760
941
1,143
899
22,891
21,423
23,601
23,818
5,667
7,137
5,987
9,315
10,495
10,071
9,386
9,971
13,056
15,879
11,315
11,346
5,563
5,587
2,082
829
776
721
664
22,810
22,810
842
674
498
49867484222,81022,8106647217768292,0825,5875,56311,34611,31515,87913,0569,9719,38610,07110,4959,3155,9877,1375,66723,81823,60121,42322,8918991,1439412,7601,6683103331,28889772599409221,0242,2352,3852,273777464055950500
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
230
221
0
0
0
0
0
0
0
0
0
0
0
0
5,707
5,781
5,855
5,929
5,705
0
5,853
1,200
0
0
0
4,652
0
0
0
0
0
0
0
0
0
0000000004,6520001,2005,85305,7055,9295,8555,7815,707000000000000221230000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,891
21,423
23,601
23,818
5,667
5,399
4,317
2,007
3,182
2,755
2,069
2,952
6,038
8,863
9,030
10,311
0
0
0
0
0
0
0
0
0
0
0
0
00000000000010,3119,0308,8636,0382,9522,0692,7553,1822,0074,3175,3995,66723,81823,60121,42322,8910000000000000000000000000000
> Total Stockholder Equity
0
2
-9
-14
-25
-32
-42
-51
-54
-71
-79
-2,186
-2,631
-2,381
3,482
2,671
0
717
442
-63
-637
-798
-1,284
-1,606
1,533
2,760
1,853
143,358
158,738
153,589
148,717
143,969
173,100
172,182
171,283
170,223
166,272
164,230
161,941
162,319
174,663
166,975
165,619
161,243
72,619
70,325
66,899
66,128
46,502
46,746
43,596
168,596
168,596
131,977
82,059
88,387
88,38782,059131,977168,596168,59643,59646,74646,50266,12866,89970,32572,619161,243165,619166,975174,663162,319161,941164,230166,272170,223171,283172,182173,100143,969148,717153,589158,738143,3581,8532,7601,533-1,606-1,284-798-637-6344271702,6713,482-2,381-2,631-2,186-79-71-54-51-42-32-25-14-920
   Common Stock
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
7
7
0
15
16
16
16
161616150776666555555555555544444111111111101111111111111110
   Retained Earnings Total Equity00000000-220,831-212,04500-114,108-107,907-101,3240-73,549-69,518-66,585-64,188-60,090-58,576-56,855-52,772-62,596-57,890-39,899-37,595-32,706-29,746-28,669-28,444-28,259-28,012-27,094-26,301-25,545-25,338-24,9160-23,145-21,892-20,939-20,404-19,947-10400000000-230
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
-28
-16
200
275
718
1,000
534
680
383
564
539
943
835
353
98
-32
-268
206
114
339
199
102
-177
-46
-56
-41
-13
-3
-13
-11
-15
-19
-21
-30
-38
-30
-32
-30
-64
-27
0
1,034
-171
-3,848
776
776-3,848-1711,0340-27-64-30-32-30-38-30-21-19-15-11-13-3-13-41-56-46-177102199339114206-268-32983538359435395643836805341,000718275200-16-2800000000000
   Capital Surplus 
0
25
0
0
0
0
0
0
0
0
25
17,788
17,788
18,357
25,098
25,098
0
25,098
25,098
25,098
25,098
25,756
25,785
25,816
29,622
31,330
31,629
176,329
193,284
193,370
206,265
206,362
225,765
229,209
229,899
230,364
230,497
230,823
231,457
235,876
0
268,308
273,540
275,367
0
0
282,402
286,986
0
0
0
0
0
0
0
0
00000000286,986282,40200275,367273,540268,3080235,876231,457230,823230,497230,364229,899229,209225,765206,362206,265193,370193,284176,32931,62931,33029,62225,81625,78525,75625,09825,09825,09825,098025,09825,09818,35717,78817,7882500000000250
   Treasury Stock00000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
25
25
25
25
25
25
25
25
25
17,788
17,788
18,357
25,098
25,098
0
25,098
25,098
25,098
25,098
25,756
25,785
25,816
29,622
31,330
31,629
176,329
193,284
193,370
206,265
206,362
225,765
229,209
229,899
230,364
230,497
230,823
231,457
235,876
265,580
268,308
273,540
275,367
276,989
282,402
283,427
286,986
290,555
300,008
301,349
0
442,305
456,812
469,810
471,325
471,325469,810456,812442,3050301,349300,008290,555286,986283,427282,402276,989275,367273,540268,308265,580235,876231,457230,823230,497230,364229,899229,209225,765206,362206,265193,370193,284176,32931,62931,33029,62225,81625,78525,75625,09825,09825,09825,098025,09825,09818,35717,78817,78825252525252525252500



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-122
Gross Profit-122-122
 
Operating Income (+$)
Gross Profit-122
Operating Expense-81,639
Operating Income-81,639-81,761
 
Operating Expense (+$)
Research Development2,709
Selling General Administrative24,174
Selling And Marketing Expenses384
Operating Expense81,63927,266
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,011
Other Finance Cost-1,423
Net Interest Income-2,435
 
Pretax Income (+$)
Operating Income-81,639
Net Interest Income-2,435
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-80,650-82,628
EBIT - interestExpense = -80,650
-80,650
-79,639
Interest Expense1,011
Earnings Before Interest and Taxes (EBIT)-79,639-79,639
Earnings Before Interest and Taxes (EBITDA)-79,517
 
After tax Income (+$)
Income Before Tax-80,650
Tax Provision-0
Net Income From Continuing Ops-80,650-80,650
Net Income-80,650
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses81,639
Total Other Income/Expenses Net9892,435
 

Technical Analysis of Renovaro Biosciences Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Renovaro Biosciences Inc. The general trend of Renovaro Biosciences Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Renovaro Biosciences Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Renovaro Biosciences Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Renovaro Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.32 < 0.419 < 0.448.

The bearish price targets are: 0.27.

Know someone who trades $RENB? Share this with them.👇

Renovaro Biosciences Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Renovaro Biosciences Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Renovaro Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Renovaro Biosciences Inc. The current macd is -0.01400558.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Renovaro Biosciences Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Renovaro Biosciences Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Renovaro Biosciences Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Renovaro Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartRenovaro Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Renovaro Biosciences Inc. The current adx is 33.14.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Renovaro Biosciences Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Renovaro Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Renovaro Biosciences Inc. The current sar is 0.41714743.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Renovaro Biosciences Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Renovaro Biosciences Inc. The current rsi is 40.89. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Renovaro Biosciences Inc Daily Relative Strength Index (RSI) ChartRenovaro Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Renovaro Biosciences Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Renovaro Biosciences Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Renovaro Biosciences Inc Daily Stochastic Oscillator ChartRenovaro Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Renovaro Biosciences Inc. The current cci is -116.52203775.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Renovaro Biosciences Inc Daily Commodity Channel Index (CCI) ChartRenovaro Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Renovaro Biosciences Inc. The current cmo is -23.87062632.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Renovaro Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartRenovaro Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Renovaro Biosciences Inc. The current willr is -85.11811024.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Renovaro Biosciences Inc Daily Williams %R ChartRenovaro Biosciences Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Renovaro Biosciences Inc.

Renovaro Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Renovaro Biosciences Inc. The current atr is 0.04201563.

Renovaro Biosciences Inc Daily Average True Range (ATR) ChartRenovaro Biosciences Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Renovaro Biosciences Inc. The current obv is 12,428,995.

Renovaro Biosciences Inc Daily On-Balance Volume (OBV) ChartRenovaro Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Renovaro Biosciences Inc. The current mfi is 20.56.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Renovaro Biosciences Inc Daily Money Flow Index (MFI) ChartRenovaro Biosciences Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Renovaro Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-28BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-31MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Renovaro Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Renovaro Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.893
Ma 20Greater thanMa 500.335
Ma 50Greater thanMa 1000.328
Ma 100Greater thanMa 2000.503
OpenGreater thanClose0.288
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Renovaro Biosciences Inc with someone you think should read this too:
  • Are you bullish or bearish on Renovaro Biosciences Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Renovaro Biosciences Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Renovaro Biosciences Inc

I send you an email if I find something interesting about Renovaro Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Renovaro Biosciences Inc.

Receive notifications about Renovaro Biosciences Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.